MeiraGTx Limited

MGTX · Nasdaq · United States

Share price · MGTX

$8.32-5.57 (-40.10%) 3M

close as of 2026-11-18 · 24h delayed · vol 585K (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when MGTX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 13 Nov 2026+4.4%
  2. 12 Nov 2026-9.2%
  3. 14 Oct 2026-5.3%

    Nothing announced by MGTX that day or the session before.

  4. 24 Sep 2026-6.0%
  5. 22 Sep 2026-5.6%

    Nothing announced by MGTX that day or the session before.

  6. 14 Aug 2026+6.7%
  7. 30 Jun 2026+7.7%

    Nothing announced by MGTX that day or the session before.

  8. 18 Jun 2026+8.7%

    Nothing announced by MGTX that day or the session before.

  9. 16 Apr 2026-15.7%

    Nothing announced by MGTX that day or the session before.

  10. 14 Apr 2026+17.2%

    Nothing announced by MGTX that day or the session before.

Share of unusual movement by asset

For each asset, the share of MGTX's own-move activity since 3 Nov 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—7%
Sessions with no dated event—93%

No dated announcements about its assets since 3 Nov 2025.

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
Glutamic acid decarboxylase (GAD) gene delivered to the subthalamic nucleusGene therapy / editing
Parkinson's Disease

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
October 2029 (1)
AAV-GAD gene therapyPhase 1/2Parkinson's Disease
Est. primary completion 2029-10 · NCT05894343 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$4.8M$39M$187M$51M-$25M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$321M$58M$145M—-$39M operating cash flowreport ↗
2026-Q1$0.3M$32M$74M$46M$18M operating cash flowreport ↗
2025-Q3$0.4M$33M$17M$51M-$12M operating cash flowreport ↗
2025-Q2$3.7M$33M$34M$39M-$44M operating cash flowreport ↗
2025-Q1$1.9M$33M$69M$40M-$37M operating cash flowreport ↗
2024-Q3$11M$26M$125M$39M-$25M operating cash flowreport ↗
2024-Q2$0.3M$35M$101M$49M-$19M operating cash flowreport ↗
2024-Q1$0.7M$34M$120M$20M-$37M operating cash flowreport ↗
2023-Q3$5.1M$28M$64M$44M-$24M operating cash flowreport ↗
2023-Q2$3.5M$20M$93M$30M-$29M operating cash flowreport ↗
2023-Q1$3.3M$22M$69M$30M-$37M operating cash flowreport ↗
2022-Q3—$17M$115M$37M-$21M operating cash flowreport ↗
2022-Q2—$24M$72M$34M-$28M operating cash flowreport ↗
2022-Q1—$23M$114M$31M-$8.3M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$81M$130M$68M$29M-$46M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$33M$119M$106M$37M-$104M operating cash flowreport ↗
2023-FY$14M$104M$131M$21M-$105M operating cash flowreport ↗
2022-FY—$86M$116M$32M-$73M operating cash flowreport ↗
2021-FY—$67M$138M$20M-$11M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 11 sales ($5.2M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-17Forbes Alexandria · director, PRESIDENT & CEOGift24,100——Form 4
2026-11-17Forbes Alexandria · director, PRESIDENT & CEOOpen-market sale62,000$8.45$524KForm 4
2026-10-20Giroux Richard · CFO & COOOpen-market sale56,000$9.95$557KForm 4
2026-10-06Naylor Stuart · CHIEF SCI OFCR, OPHTHALMOLOGYOpen-market sale27,659$10.64$294KForm 4
2026-09-23SEBULSKY ALAN · directorAward / grant (derivative)100,000——Form 4
2026-08-18Forbes Alexandria · director, PRESIDENT & CEOOpen-market sale62,000$13.86$859KForm 4
2026-07-21Giroux Richard · CFO & COOOpen-market sale56,000$12.51$701KForm 4
2026-07-07Naylor Stuart · CHIEF SCI OFCR, OPHTHALMOLOGYOpen-market sale2,547$13.86$35KForm 4